AYTU on Nasdaq
AYTU BIOPHARMA, INC
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Nektar Therapeutics, Journey Medical Corp or Agios Pharmaceuticals, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
64.0%Gross margin2
-14.4%Operating margin2
-24.8%Net margin2
-13.3%Revenue growth, 20262
-40.4%Return on equity2
0.26×Debt to equity2
$3.3MFree cash flow2
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue36¢$20.8M
- Other costs64¢$36.8M
- Income tax0¢$21.0K
Out of $57.6M in revenue.2 The company lost money this year.
Where each dollar of operating cash went, fiscal 2026
- Capital spending1¢$29.0K
- Kept or used elsewhere99¢$3.3M
Out of $3.3M of cash from operations.2
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Net revenue | $57.6M | $66.4M |
| Cost of goods sold | $20.8M | $20.6M |
| Gross profit | $36.8M | $45.8M |
| Selling and marketing | $23.4M | $20.9M |
| General and administrative | $19.3M | $17.4M |
| Research and development | $0 | $1.3M |
| Amortization of intangible assets | $2.5M | $3.7M |
| Restructuring costs | $0 | $2.1M |
| Impairment expense | $0 | $8.3M |
| Total operating expenses | $45.1M | $53.7M |
| Loss from operations | -$8.3M | -$7.8M |
| Other income (expense), net | $713.0K | -$512.0K |
| Interest expense | -$1.9M | -$3.7M |
| Derivative warrant liabilities loss | -$4.7M | -$1.7M |
| Loss from continuing operations before income tax expense | -$14.2M | -$13.7M |
| Income tax expense | -$21.0K | -$437.0K |
| Net loss from continuing operations | -$14.3M | -$14.2M |
| Net income from discontinued operations, net of tax | $0 | $620.0K |
| Net loss | -$14.3M | -$13.6M |
| Basic and diluted weighted-average common shares outstanding (in shares) | 12.3M shares | 6.3M shares |
| Basic and diluted - continuing operations (in dollars per share) | -$1 | -$2 |
| Basic and diluted - discontinued operations, net of tax (in dollars per share) | $0 | $0 |
| Basic and diluted - net loss (in dollars per share) | -$1.16 | -$2.16 |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Cash and cash equivalents | $26.3M | $31.0M | |
| Accounts receivable, net | $22.8M | $31.2M | |
| Inventories | $6.9M | $11.4M | |
| Prepaid expenses and other current assets | $5.8M | $5.6M | |
| Total current assets | $61.8M | $79.2M | |
| Property and equipment, net | $385.0K | $532.0K | |
| Operating lease right-of-use assets | $857.0K | $1.1M | |
| Intangible assets, net | $41.4M | $42.2M | |
| Other non-current assets | $601.0K | $1.2M | |
| Total non-current assets | $43.2M | $45.0M | |
| Total assets | $105.0M | $124.2M | |
| Accounts payable | $11.3M | $10.6M | |
| Accrued liabilities | $35.2M | $38.2M | |
| Revolving credit facility | $6.1M | $9.1M | |
| Current portion of debt | $1.9M | $1.9M | |
| Other current liabilities | $239.0K | $3.4M | |
| Total current liabilities | $54.7M | $63.1M | |
| Debt, net of current portion | $9.1M | $10.9M | |
| Derivative warrant liabilities | $1.2M | $26.3M | |
| Other non-current liabilities | $4.8M | $4.9M | |
| Total non-current liabilities | $15.1M | $42.1M | |
| Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding | $0 | $0 | |
| Common stock, par value $.0001; 200,000,000 shares authorized; 10,728,208 and 8,976,913 shares issued and outstanding, respectively | $1.0K | $1.0K | |
| Additional paid-in capital | $383.1M | $352.5M | |
| Accumulated deficit | -$347.8M | -$333.5M | |
| Total stockholders equity | $35.3M | $19.0M | $27.7M |
| Total liabilities and stockholders equity | $105.0M | $124.2M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, authorized (in shares) | 50.0M shares | 50.0M shares | |
| Preferred stock, issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, authorized (in shares) | 200.0M shares | 200.0M shares | |
| Common stock, issued (in shares) | 10.7M shares | 9.0M shares | |
| Common stock, outstanding (in shares) | 10.7M shares | 9.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Net loss | -$14.3M | -$13.6M |
| Impairment expense | $0 | $8.3M |
| Depreciation, amortization and accretion | $3.9M | $5.4M |
| Stock-based compensation expense | $691.0K | $576.0K |
| Derivative warrant liabilities loss | $4.7M | $1.7M |
| Amortization of debt discount and issuance costs | $113.0K | $108.0K |
| Inventory write-down | $2.2M | $325.0K |
| Other non-cash adjustments | $44.0K | $752.0K |
| Non-cash adjustments from discontinued operations | $0 | $254.0K |
| Accounts receivable, net | $8.4M | -$7.6M |
| Inventories | $2.4M | $382.0K |
| Prepaid expenses and other current assets | -$176.0K | -$451.0K |
| Accounts payable | -$2.3M | $287.0K |
| Accrued liabilities | -$3.1M | $886.0K |
| Other operating assets and liabilities, net | $696.0K | $528.0K |
| Changes in operating assets and liabilities from discontinued operations | $0 | $264.0K |
| Net cash from operating activities | $3.3M | -$1.9M |
| Cash received from sales of fixed assets | $0 | $668.0K |
| Cash payments for fixed asset purchases | -$29.0K | -$228.0K |
| Cash payments for acquired intangible assets | $0 | -$3.0M |
| Net cash from investing activities | -$29.0K | -$2.6M |
| Net proceeds from issuance of common stock and warrants | $0 | $14.8M |
| Payments made to fixed payment arrangement | -$3.0M | -$6.0M |
| Net payments made to revolving credit facility | -$3.0M | $6.7M |
| Payments made to borrowings | -$1.9M | -$1.9M |
| Proceeds from borrowings | $0 | $1.9M |
| Payments for debt issuance costs | $0 | -$49.0K |
| Net cash from financing activities | -$7.9M | $15.4M |
| Net change in cash and cash equivalents | -$4.6M | $10.9M |
| Cash payments for interest | $1.8M | $2.8M |
| Cash payments for income taxes | $211.0K | $1.4M |
| Change in acquired intangible asset accruals | $3.0M | $0 |
| Other non-cash investing and financing activities | $0 | $483.0K |
Former names
Recent filings
- Sep 22, 20268-K
- Sep 22, 202610-K
- Aug 14, 2026SCHEDULE 13G/A
- Jul 30, 20264
- Jul 30, 20264
- Jul 30, 20264
- Jul 30, 20264
- Jul 30, 20264
- Jul 30, 20264
- Jul 30, 20264
- Jul 30, 20264
- Jun 25, 20268-K
- May 13, 20268-K
- May 13, 202610-Q
- Apr 2, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11